Issue
Alert me when new journal issues are available via or via
GENERAL AND SUPPORTIVE CARE
Treatment of cancer-related anemia with epoetin alfa: a review Erminia Ferrario, Leonardo Ferrari, Paolo Bidoli, Daniela De Candis, Michele Del Vecchio, Sara De Dosso, Roberto Buzzoni, Emilio Bajetta pages 563-575 Abstract | Full Text | Full-Text PDF (355 KB)
LABORATORY–CLINIC INTERFACE
Peroxisome proliferator-activated receptor-γ ligands as cell-cycle modulators Stamos Theocharis, Alexandra Margeli, Philippe Vielh, Gregory Kouraklis pages 545-554 Abstract | Full Text | Full-Text PDF (241 KB)
CONTROVERSY
Endothelial cell effects of cytotoxics: balance between desired and unwanted effects F.Y.F.L. de Vos, P.H.B. Willemse, E.G.E. de Vries, J.A. Gietema pages 495-513 Abstract | Full Text | Full-Text PDF (288 KB)
ANTI-TUMOUR TREATMENT
The treatment of brain metastases in melanoma patients D. Bafaloukos, H. Gogas pages 515-520 Abstract | Full Text | Full-Text PDF (171 KB)
COMPLICATIONS OF TREATMENT
New approaches to prevent intestinal toxicity of irinotecan-based regimens Andrea Alimonti, Alain Gelibter, Ida Pavese, Francesco Satta, Francesco Cognetti, Gianluigi Ferretti, Debora Rasio, Aldo Vecchione, Mario Di Palma pages 555-562 Abstract | Full Text | Full-Text PDF (187 KB)
Recent advances in management of small-cell lung cancer Yu Jo Chua, Christopher Steer, Desmond Yip pages 521-543 Abstract | Full Text | Full-Text PDF (309 KB)
EVIDENCE-BASED ONCOLOGY
Initial high dose chemotherapy plus autologous stem cell support improves survival outcomes compared with a standard CHOP regimen in people with higher intermediate risk aggressive lymphoma: Abstracted from: Milpied N, Deconinck E, Gaillard F, et al. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med 2004;350:1287–95. Axel Glasmacher pages 577-582 Full Text | Full-Text PDF (245 KB)
Switching to exemestane after 2–3 years of adjuvant tamoxifen prolongs disease-free survival, but not overall survival, in postmenopausal women surviving primary breast cancer, compared with continuous tamoxifen: Abstracted from: Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350:1081–92. Christina Davies pages 583-588 Full Text | Full-Text PDF (248 KB)
High-quality evidence in oncology from 17th February to 13th April 2004: a summary pages 595-596 Full-Text PDF (128 KB)
Autologous tumour cell vaccine may reduce risk of tumour progression in people with primary renal cell carcinoma: Abstracted from: Jocham D, Richter A, Hoffmann L et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet 2004;363:594–599. Chris Coppin pages 589-593 Full Text | Full-Text PDF (234 KB)
Editorial board page CO2 Full-Text PDF (49 KB)
Articles to appear in forthcoming issues page 597 Full-Text PDF (105 KB)
Copyright © 2010 Elsevier, Inc. All rights reserved | Privacy Policy | Terms & Conditions | Feedback | About Us | Help | Contact Us | The content on this site is intended for health professionals.
